[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8401 to 8425 of 8900 messages
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
22/1/2020
08:50
That’s right someuwin, I believe they market the Elast-Eon related stuff as “QuadrasilR21;. If you recall recently, Biomerics tweeted how proud they are of their partnership with little old Aortech, an out-of-character acknowledgement by them of a “little company”! As Nextlink alluded to at the time, it may well be that they have started to realise that there are probably substantial benefits available if Elast-Eon gains further traction in medical devices and that they had better get with the programme. With RUA now getting in on the act of creating devices containing Elast-Eon, albeit (I assume) still sourcing the raw polymer from Biomerics, the latter might perhaps see that they could lose some device business to the likes of RUA and Medibrane over time. It’s in Biomerics’ interest to do more promoting of Elast-Eon/Aortech.
bones
21/1/2020
22:15
In the above image you can see the QUADRA logo. I didn't realise but that includes AOR's Elast-Eon... "The Elast-Eon family of polyurethanes is also part of a larger group of products known as Quadra. Quadra products are medical polyurethanes used in a variety of medical device applications. They are specifically engineered to meet the demanding quality and biocompatibility requirement for the medical device market and are ISO-10993 and USP Class VI complaint."
someuwin
21/1/2020
21:48
Biomerics heading to California for MD&M West Show, as well as RUA Medical and AOR. [PRESS RELEASE] - Biomerics to Showcase Balloon Molding and Material Capabilities at MD&M West Show. http://ow.ly/bt1g50y1bpg If you're coming to the show, we'll be at Booth #1662. We'd love to chat and see what you are working on! #advmfgexpo #medtech #engineering #showcase https://biomerics.com/biomerics-to-showcase-balloon-molding-and-material-capabilities-at-mdm-west-show/
someuwin
21/1/2020
15:27
35,000 votes for 6,000 against
landy90
21/1/2020
14:56
"In the short run, the market is a voting machine but in the long run it is a weighing machine"
the stigologist
21/1/2020
13:23
Thanks, someuwin, I think that is how I read the RNS with Aortech getting quality licensing income from the use of Elast-Eon by RUA in new devices.
bones
21/1/2020
13:13
I sent Bill an email and got the following reply... "Thanks We are very excited by this, RUA have demonstrated high quality engineering skills and have now gained a good deal of information on how to make things out of Elasteon. We have had a couple of enquiries recently that are looking for more than just the material but design and manufacturing help. Rather than pass by , we have done a similar deal with RUA as the Medibrane license a month or so back. I personally think 2020 will be great for AorTech and its shareholders if the market ever gives us any credit. Will keep plugging away." William D Brown Chairman
someuwin
21/1/2020
12:45
I would be in favour of someone like Hardman taking a look at AOR.
langland
21/1/2020
12:28
No, true, not at current status but it must be an aspiration given the target market or at least the biggest one in the device world. In the meantime, what wider audience were you driving at? I wonder what the brokers, Shore, are doing on their end of the bargain?
bones
21/1/2020
11:40
Bones, I think the US corporates are aware of what is going on, not sure of appetite from US for a £14m mkt cap AIM stock at the moment.
landy90
21/1/2020
10:23
Reading between the lines, Landy, a widening audience must include US investors, surely.
bones
21/1/2020
10:13
Agree Landy but with the shares being tightly held and the cap only being £14m, I assume it’s difficult to attract Institutional shareholders. It is certainly appealing to private investors with a philanthropic interest.
semper vigilans
21/1/2020
10:02
They need to think about widening the audience..
landy90
21/1/2020
10:01
This news adds to the underwriting of the share price. Sometimes one wonders what it takes to stimulate interest as now I think we all take tech advances for granted.
semper vigilans
21/1/2020
09:56
Sounds promising then, Landy90! Shame the market doesn’t seem to have noticed or realised the implications, judging by just three trades today, including someone running from the opportunity :)
bones
21/1/2020
09:37
Here are a range of medical device products and systems that the RUA Medical team have worked on: •Straight, tapered and bifurcated vascular and endovascular tubular implants •Male and Female Urinary Incontinence systems •Mechanised sewing of wire scaffolds onto circular, tapered and bifurcated endovascular implant fabrics. •Woven tapered bifurcated vascular and endovascular delivery systems •Spinal lumber stabilisation implants •AAA and thoracic stent grafts •Synthetic spinal disc replacement implants •Pelvic organ prolapse mesh systems •3D tissue growth support scaffolds (permanent & reabsorbable) •Synthetic ligaments •PTFE mesh and implantable fabrics •Hernia mesh systems •Reabsorbable and composite mesh systems •Cuff fabrics •Stent covering systems •Knitted pessary system •Medical Coatings •Silver Ion release urology catheters. •Reabsorbable and composite mesh systems •Antimicrobial solutions •Alginate wound care systems •Personal care systems •Catheter securement system •Braided Suture Systems •Blood monitoring system •Heart Surgery retractor •Knitted and woven dental floss systems •Single use instruments https://www.ruamedical.com/services/products/
someuwin
21/1/2020
09:27
Bones This looks like a shift from "if you are interested in Elasteon, go buy it from Biomerics" to "you should be considering Elasteon for your device and we are the experts in making things with it". Importantly RUA has all the certification and FDA approved facilities to take a project way beyond R&D. Its much bigger than just replacing animal tissue.
landy90
21/1/2020
09:22
Https://mdmwest.mddionline.com/ Speeding Medical Devices to Market “By 2025 the global medical device manufacturing market is expected to exceed $200 billion, driven by the aging population, increasing prevalence of chronic diseases, advancements in technology, and other factors. As medtech surges ahead, professionals in this dynamic industry need one place to cross paths annually to swap ideas, find inspiration, overcome challenges, and source products to keep their engineering projects humming. Enter Medical Design & Manufacturing (MD&M) West — the world's largest medical design and manufacturing event. MD&M West, now in its 35th year, is where engineers and executives from across the globe converge before going on to change the lives of patients. In addition to the three-day conference covering medtech, 3D printing, and smart manufacturing, the event offers the opportunity to meet suppliers and experts leading the charge to disrupt healthcare.“
bones
21/1/2020
08:37
Today's news is excellent. First we had the new licence agreement with Medibrane, Now this extension with RUA. All working to increase the number of Elast-Eon enabled medical devices. AOR is really setting itself up to become a big player in time. And still valued at only £14m - amazing!
someuwin
21/1/2020
08:34
I wonder if this is all related to extending the idea of replacing devices that use animal tissue with polymers, or whether it is more generally part of a strategy to promote Elast-Eon in devices whether or not they currently use animal tissue. For example, under the new licence with Medibrane, that agreement is allowing Medibrane to expand their existing polymer coating business so that Elast-Eon can be designed into new products and promoted to device companies. Medibrane has identified that Elast-Eon has certain advantages over other polymers. This has nothing to do with replacing animal tissue sourced devices. There seems now to be developing an industry trend, perhaps even a need, to recognise that alternative technologies are emerging and that Elast-Eon, that already is proven in human use and has an FDA Master File status, may be the “go to” material for quality and flexibility. If Aortech and RUA Medical can leverage their current groundbreaking work on the grafts and patches (and perhaps the heart valve?), they could become a “go to“ supplier to some of the biggest majors about today. At least I imagine that must be the thinking here.
bones
21/1/2020
08:22
There we all are looking forward to the new medical devices to provide the growth when it seems as if the jewel in the crown, Elast-Eon has been there waiting all along, underappreciated and undersold. Great to see this being rectified and can only enhance the long term value and attractiveness of AOR.
greedy rooster
21/1/2020
08:18
A real flair for explicating matters.
the stigologist
21/1/2020
08:16
Missed the final part, it looks like Bill and David are off for some winter sun together in California.
landy90
21/1/2020
07:50
Nicely summed up.
langland
21/1/2020
07:48
Interesting development, moving the polymer business up the value chain and creating a centre of excellence for device companies to go to toget things made. Best is they are responding to market demand so potential customers are ready for RUA
landy90
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210921 16:35:31